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Abstract  
Folic Acid (FA)-tagged protein nanoemulsions were found to be preferentially 
internalized on B-cell lymphoma cell line (A20 cell line), which, for the first time, are 
reported to express folate receptor (FR)-alpha. Carbon monoxide releasing molecule-2 
(CORM-2) was incorporated in the oil phase of the initial formulation.  FA-
functionalized nanoemulsions loaded with CORM-2 exhibited a considerable antitumor 
effect and an increased survival of BALB/c mice bearing subcutaneous A20 lymphoma 
tumors. The developed nanoemulsions also demonstrated to be well tolerated by these 
immunocompetent mice. Thus, the results obtained in this study demonstrate that FA-
tagged protein nanoemulsions can be successfully used in cancer therapy, with the 
important ability to delivery drugs intracellularly.  
 
 
 
Keywords: protein nanoemulsions; folic acid; CORM-2; specific uptake; targeted drug 
delivery  
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Background 
Nanocarriers can modulate the pharmacokinetic and drug tissue distribution 
profile.
1, 2
 Specific anticancer drug delivery is promoted including targeting ligands,
1, 3-5
 
such as folic acid (FA).
6
 FA and FA conjugates bind with high affinity to folate receptor 
(FR)-alpha and –beta, and enter FR-expressing cells by receptor-mediated endocytosis.7 
FR-alpha expression is restricted to various normal epithelial cells, however it is 
overexpressed in several malignant cells and tissues.
8
 FR-beta is a differentiation 
marker in normal hematopoiesis, being restricted to the myelomonocytic lineage and 
increasing during neutrophil maturation. FR-beta expression is also increased in 
activated monocytes/macrophages.
8
 FA has emerged as a optimal targeting ligand with 
simple conjugation chemistry, non-immunogenicity and high affinity for the FR (Kd = 
10
-10
 M) even after conjugation.
9
 Nanocarriers functionalized with FA are widely 
studied for cancer targeting aplications. 
Carbon monoxide (CO) has shown beneficial effects in mammals.
10-13
 CO can 
induce growth arrest of human cancer cells, as well as murine AC29 mesothelioma 
cells.
14
 The first compound described as able to carry and deliver controlled quantities 
of CO in cellular systems was the tricarbonyldichlororuthenium(II) dimer 
([Ru(CO)3Cl2]2), known as CORM-2 (Carbon monoxide releasing molecule-2).
10, 11, 15-17 
Ru has also been used independently in a variety of experimental anti-cancer drugs, 
with no acute or sub-acute toxicities reported.
15, 18 
CORMs have been described as exhibiting a wide range of biological effects 
resulting in specific responses, which involve a restricted number of intracellular 
pathways and targets that encompass inflammation, apoptosis and cellular 
proliferation.
16
  CORM-2, in particular, has been described to promote a beneficial 
therapeutic outcome in a number of mouse models of human disease.
15
 However, 
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CORM-2 has been shown to be highly unstable in plasma. Together with its observed 
anti-proliferative capacity,
19, 20
 this support the advantage of targeted delivery of 
CORM-2 to cancer cells. 
Here, we report the development of FA-tagged protein nanoemulsions loaded with 
CORM-2 for targeted drug delivery in a B-cell lymphoma model. Nanoemulsions were 
produced by high pressure homogenization of an aqueous phase (BSA solution 
containing a PEGylated surfactant and BSA-FA conjugate) with an organic phase 
(vegetable oil). Small, stable, PEGylated (described elsewhere
21
) and FA-functionalized 
nanoemulsions were obtained and evaluated in terms of specific uptake using a 
lymphoma cell line (A20 cell line). The biological effect of the nanoemulsions loaded 
with CORM-2 was tested both in vitro and in vivo. The results obtained suggest the use 
of FA-tagged protein nanoemulsions for targeted drug delivery in cancer therapy.  
 
 
Methods 
Nanoemulsion preparation  
Nanoemulsions were prepared using a high pressure homogenizer (APV-2000, 
Denmark). BSA (Sigma-Aldrich, USA) and PEGylated surfactant (Sigma-Aldrich, 
USA) were dissolved in phosphate buffer saline (PBS), pH 7.4, at concentration of 10 
mg/mL and 5 mg/mL, respectively. In this aqueous phase was also introduced a 
fluorescent agent using Fluorescein isothiocyanate (FITC) labelled-BSA (Sigma-
Aldrich, USA) at a 1:20 ratio (m/m) relatively to BSA protein. BSA-FA conjugate 
solution, previously prepared, was added at a 1:100 ratio (m/m) to the aqueous phase. 
The aqueous solution was emulsified with an organic solvent (vegetable oil) by 
subjecting the initial formulation to high pressure homogenization. The drug, CORM-2, 
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was dissolved in vegetable oil phase. 
 
Conjugation of FA with BSA 
FA (Sigma-Aldrich, USA) dissolved in PBS, pH 7.4, was ‘activated’ with 5-fold excess 
of N-(3-dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride (Sigma-Aldrich, 
USA) and a 1-fold excess of N-hydroxysulfosuccinimide (Sigma-Aldrich, USA) for 2 
hours at room temperature. Activated FA was then added to BSA using a 75:1 FA to 
BSA moles ratio, and then left to react for 8-10 hours. Dialysis against PBS was 
performed for 8 days in order to remove the excess FA and other reactants from the 
conjugated protein. The purified BSA-FA conjugate contained 35 moles of FA per 1 
mole of BSA. 
 
Physicochemical characterization 
The size distribution and zeta-potential values of the nanoemulsions were determined at 
pH 7.4 (PBS buffer) and at 25ºC, using dynamic light scattering in a Malvern zetasizer 
NS, by photon correlation spectroscopy (PCS) and by electrophoretic laser Doppler 
anemometry, respectively. The values for viscosity and refractive index were taken as 
0.890 cP and 1.330, respectively. The protein concentration was kept constant at 10 
mg/mL. 
 
Cells and culture conditions 
B-cell lymphoma cell line (A20 cell line) (ATCC, TIB-208) was obtained from 
American Type Culture Collection (LGC Standards, UK).  
The A20 cell line was grown in suspension in Petri dishes, that were not tissue culture 
treated (Sarstedt, Germany), using RPMI-1640 medium supplemented with 10% (v/v) 
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of FBS; 1% (v/v) of penicillin/streptomycin solution; 2 mg/mL of sodium bicarbonate; 
0.05 mM of 2-mercaptoethanol. Exponentially growing culture was maintained in a 
humidified atmosphere of 5 % CO2 in air at 37 °C. 
 
Protein extraction and Western blot analysis for FR confirmation in the A20 cell line 
48h-incubated cells (KB, A20 and K562 cell lines) were harvested, centrifuged at 2000 
rpm (4º C) for 10 min and washed in cold PBS. Following another centrifugation, at 
6000 rpm (4ºC) for 3 min, cell pellets were resuspended, homogenized in 100 μl of ice-
cooled radioimmunoprecipitation (RIPA) buffer (1% NP-40 in 150 mM NaCl, 50 mM 
Tris-HCl pH 7.5, 2 mM EDTA), supplemented with 20 mM NaF, 1 mM 
phenylmethylsulfonyl fuoride (PMSF), 20 mM Na2V3O4, a protease inhibitor cocktail 
(Roche, Germany), and then incubated for 10 min. The proteins were cleared by 
centrifugation at 10 000 g (4º C) for 10 min. The soluble protein concentration was 
determined using Bio-Rad DC protein assay (Bio-Rad Laboratories, USA). The BSA 
was considered as a control. 40 μg of the resulting cytosolic protein extracts was 
separated through 12% sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis, and transferred onto a Hybond®-P polyvinylidene difluoride membrane 
(GE Healthcare Life Sciences, USA). 5% (w/v) nonfat dry milk in PBS with 0.05% 
Tween-20 (TPBS) was used for blocking nonspecific protein binding. After 2 hours of 
blocking incubation, the membrane was washed three times with TPBS. The membrane 
was then incubated overnight (4°C) with primary antibody monoclonal rabbit to FA 
binding protein (Abcam®, United Kingdom), diluted in 1% BSA (w/v) in TBST 
(1:1000). Horseradish-peroxidase-conjugated secondary antibody (anti-rabbit IgG-HRP, 
Cell Signaling Technology Inc., USA) was diluted in 5% (w/v) nonfat dry milk in 
TBST (1:30000). Subsequent membrane incubation (1 hour, room temperature) was 
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following by three TPBS washes. Immobilon solutions (Millipore, USA) were used for 
chemiluminescent detection in the Chemi Doc XRS system. β-actin was used as loading 
control.  
 
Cell viability assay 
A20 cell viability was studied using the Promega CellTiter 96
®
 AQueous Non-
Radioactive Cell Proliferation (MTS) assay (Promega, USA). Cells were seeded in 24-
well tissue culture plates (Nunc, Denmark) at a density of 5×10
4
 cells/well and co-
incubated with treatment conditions for determined incubation times. After co-
incubation, MTS was added and the cells were incubated for a further 4 hours at 37ºC. 
After this period, the absorbance of the formazan product was read at 490 nm, using 
Spectra MAX 340PC microwell plate reader. Cell viability was expressed as a 
percentage relative to the negative control.  
 
Uptake assay 
Unbound BSA-FITC and BSA-FA were removed using Centricon tubes (Amicon Ultra-
15, Millipore) and then the uptake of the nanoemulsions was evaluated. A20 cells were 
seeded at a density of 1×10
5
 cells/well on coverslips pre-treated with Poly-L-lysine 
(Sigma-Aldrich, USA), and co-incubated with nanoemulsions for 4 hours. Solutions of 
nanoemulsions were prepared in FA-free Hanks’ Balanced Salt solution (HBSS 
medium) (Lonza, Belgium). Cells were washed with cold PBS and fixed with 500 µL of 
paraformaldehyde 4% (v/v) for 30 minutes and then permeabilized with Triton 0.1% 
(v/v) solution. After more two washing steps with PBS, cells were incubated with 5 
units/mL of Alexa Fluor 568 Phalloidin (Molecular Probes by Life Technologies, USA). 
2 µL of Permafluor (Thermo Scientific, United Kingdom) containing 5 µg/mL of 
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Hoechst (Molecular Probes by Life Technologies, USA) was used for place coverslips 
on slides. Confocal observations were performed using an inverted Zeiss confocal laser 
scanning microscope (CLSM; Olympus Fluoview FV1000) and three dimensional 
models were produced, using the software Imaris image analysis program. 
 
In vivo studies 
All animal experiments were performed after institutional ethical approval and in 
agreement with national (Portuguese Veterinary Office) and international rules 
(FELASA - Federation of Laboratory Animal Science Associations) on animal welfare. 
Experiments were performed in agreement with Instituto de Medicina Molecular Ethical 
Regulations and the ethical approval was given under the project "Therapeutic 
evaluation of anti-cancer drugs in mouse models of cancer” licensed to Dr. Gonçalo 
Bernardes. Under those strict indications (3R’s- reduce, replacement and refinement) 
the minimal number of animals calculated was 5 mice per group, which was considered 
sufficient for the purpose of this investigation. Immunocompetent 10-weeks-old female 
BALB/c mice were subcutaneously injected with A20 cells. BALB/c mice bearing 
subcutaneous A20 lymphoma tumors were treated intravenously with 200 μL of FA-
functionalized nanoemulsions loaded CORM-2 (targeting FR), 200 μL of FA-
functionalized nanoemulsions (carrying no drug), 200 μL of CORM-2 (non-targeted 
delivery of drug), or saline. The dose was chosen according to the safety profile already 
reported for CORM-2 in in vivo studies.
11
 Therapy was initiated when tumors reached 
80-120 mm
3
 and a daily treatment was performed for 5 days. The mice were sacrificed 
once tumor reached a volume greater than 1000 mm
3
, which is the general procedure for 
therapeutic assessment. The readout of the experiment is tumor volume which can be 
then translated into survival - survival here means the number of days mice took for 
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tumors to reach a volume greater than 1000 mm
3
. Mice body weight variations, during 
and after therapy, and survival curves for the different treatments applied were also 
determined.  
Normal rodent feed contains a high concentration of FA (6 mg/kg feed), so mice 
were fed a FA-free diet (Harlan diet TD90261, Harlan Teklad) beginning 2 weeks 
before tumor implantation and maintained throughout the study in order to maintain 
serum FA concentrations closer to the range of normal human serum.
22, 23
 Being these 
mice most commonly used for evaluating the performance of most anticancer agents 
and the high FA levels in mice sera could negatively affect the performance of FA-drug 
formulations used for cancer therapy, the majority of “FA-targeted” pharmacological 
studies published had involved the use of animals that were acclimated to some form of 
low/free FA chow.
23, 24 
 
Statistical analysis 
Assumptions were met prior to data analysis. All data were tested for normality 
(Kolmogorov-Smirnov test) and homoscedasticity (Levene’s test). To investigate the 
influence of PEGylated BSA nanoparticles with(out) CORM-2 on cell viability, a one-
way ANOVA was conducted, with six levels: nanoemulsions, FA-nanoemulsions, 
nanoemulsions+CORM-2, FA-nanoemulsions+CORM-2, CORM-2 and death control 
(30% DMSO). Post hoc comparisons were conducted using Student-Newman-Keuls 
(SNK). A P value of 0.05 was used for significance testing. Analyses were performed in 
STATISTICA (StatSoft v.7, US). 
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Results 
FA-tagged protein nanoemulsions and specific uptake by FR positive cells 
We produced BSA nanoemulsions by high pressure homogenization of a BSA 
solution, containing a PEGylated surfactant, with vegetable oil (Table 1). The 
characterization of these protein nanoemulsions  is presented in Table 2 and is in line 
with what was previously described by our group, demonstrating that the particles are 
small, neutral surface (zeta-potential close to zero) and present high stability along 
time.
21
 All these results establish that these PEGylated protein nanoemulsions have 
suitable characteristics required for systemic administration.  Nanoemulsions containing 
imaging and targeting agents were prepared by introducing of BSA-FITC and BSA-FA 
conjugate in aqueous phase of initial formulation (Table 1). To determine if FA at the 
nanoemulsion particle’s surface promotes specific cell targeting and the endocytosis, the 
cellular uptake of nanoemulsions was evaluated in a B-cell lymphoma cell line (A20 
cell line).  
B-cell lymphoma is one of the most common hematologic malignancies and 
targeted therapy based on monoclonal antibodies has become a treatment of choice in 
the clinic. However, a substantial number of patients experience a clinical relapse as a 
consequence of poor or no response to the treatments.
25
 Several new targeting ligands 
have recently emerged for B-cell lymphoma treatment.
26
 We confirmed by western blot 
that FR-alpha is expressed in A20 cells (Figure 1A), reported here for the first time. The 
KB cell line was used as FR positive control and K562 cell line as FR negative control.  
The evaluation of specific cellular uptake of nanoemulsions was performed by 
confocal laser scanning microscopy. It was observed that FA-functionalized 
nanoemulsions are more efficiently internalized by A20 cells (Figure 1B). These results 
suggest that FA-functionalized nanoemulsions interact efficiently with FR-alpha at the 
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cellular surface and promote FR-mediated endocytosis. By staining with phalloidin, 
which is a high-affinity F-actin probe, we showed that the nanoparticles were indeed 
internalized by the A20 cells. 3D reconstructions of images obtained by confocal 
microscopy allowed determining the number of nanoparticles internalized per cell 
(Figure 1B). We observed that, in average, approximately 7 fold more nanoparticles 
were internalized when FA is on the particle’s surface. 
 
FA-tagged protein nanoemulsions loaded with CORM-2 and specific drug delivery 
We also evaluated the capacity of these BSA nanoemulsions for the selective 
delivery of drugs into FR expressing cells. We used CORM-2 as a model compound due 
to its described anti-proliferative capacity against cancer cells and its instability in 
plasma, which makes it an ideal candidate for encapsulation and targeted delivery. 
Taking into account the production method described, the prepared nanoemulsions are 
especially efficient for the entrapment of hydrophobic drugs, such as CORM-2. The 
physicochemical characterization of the nanoemulsions containing FA at the surface and 
CORM-2 encapsulated was performed and we observed that the values of size, 
polydispersity index (PDI) and zeta-potential are very similar to the values presented by 
the nanoemulsions (Table 2). The quantification of FA in these nanoemulsions was also 
performed using RIDASCREEN®FAST Folic acid test kit and the results showed a 
high concentration of FA at the surface of nanoemulsions (Table 2). 
In order to understand the mechanism responsible for the CORM-2 induced anti-
proliferative effect observed in A20 lymphoma cells (Figure 2A), and taking into 
account the known link between CO and HO-1, we evaluated HO-1 expression and 
ROS levels in A20 exposed to different concentrations of CORM-2. We verified an 
increase of HO-1 protein expression in the presence of CORM-2, as reported in other 
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pathologies (e.g. in kidney cells),
27
 determined by Western blot analysis (Supporting 
information, Figure S1), however ROS production was not significantly altered 
(Supporting information, Figure S2).   
FA-functionalized nanoemulsions loaded with CORM-2 were shown to have the 
same anti-proliferative effect than CORM-2 alone, which diffused across the cell 
membrane. This result demonstrated that these nanoemulsions recognized the FR 
present in surface of A20 cells, being internalized by FR-mediated endocytosis and 
releasing the drug, as intended. Additionally, the drug encapsulated in the 
nanoemulsions present several advantages for in vivo applications, as previously 
described. This decrease in cell proliferation is significantly different from the anti-
proliferative effect observed for the empty nanoemulsions, whether FA-functionalized 
or not, and the non-targeted nanoemulsions containing CORM-2 (F(5,12)=138,304, 
P<0.05)  (Figure 2B). Nanoemulsions containing CORM-2, but not FA at the surface 
(non-targeted nanoemulsions), are not efficiently internalized by A20 cells and the drug 
remains protected, which explains the absence of anti-proliferative effect. These results 
suggest a preferential internalization of the FA-functionalized nanoemulsions by these 
FR positive cancer cells and also indicates an effective release of the drug from 
nanoemulsions in vitro. 
The bioavailability and targeting specificity of these FA-functionalized 
PEGylated BSA nanoemulsions was also tested in vivo. Their therapeutic efficacy was 
tested in BALB/c mice bearing subcutaneous A20 lymphoma tumors. This syngeneic 
model mimics human disease in an immunocompetent host with aspects of diffuse large 
B-cell lymphomas,
28, 29
 which in our view is clinically relevant. The subcutaneous 
model has additional advantages, such as providing visual confirmation that mice do 
have tumors prior to therapy and easy assessment of tumor response or growth over 
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time.
30
 
 Figure 3A shows a considerable tumor growth inhibition when mice were 
treated with FA-functionalized nanoemulsions loaded with CORM-2, whilst empty FA-
functionalized nanoemulsions were shown to have no effect. The treatment with FA-
functionalized nanoemulsions containing CORM-2 substantially increased mice 
survival (Figure 3B). The in vivo study also demonstrated that the disclosed PEGylated 
BSA nanoemulsions were well tolerated in immunocompetent mice, with no detectable 
weight loss (Figure 3C). 
 
 
Discussion 
We have developed FA-functionalized BSA nanoemulsions that demonstrated 
specific drug delivery into FR positive cancer cells. The expression of FR-alpha was 
confirmed in A20 B-cell lymphoma cells that were successfully targeted by FA-
functionalized BSA nanoemulsions.  
CORMs, as CO, induce specific biological responses, through activation of a 
few intracellular pathways and targets, regulating inflammation, apoptosis and cellular 
proliferation.
16
 CO has the ability to block cancer cell proliferation.
11
 It appears that CO 
exerts its effect through different pathways in different cell lines and under different 
conditions.
11, 16
 One of the central targets of CO seems to be the mithocondria and the 
overall bioenergetics of the cell. CO may promote mitochondrial biogenesis and drive 
mitochondria to increase ATP and ROS generation that in turn influence cellular 
behavior. Increasing ROS production would ultimately lead to induction of HO-1, 
which under certain circumstances may generate a positive feedback loop that 
contributes to the long-lasting beneficial effects of the HO1–CO pathway, perhaps 
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involving other HO-1 products.
11
 Our results indicate that in A20 cells, CORM-2 does 
in fact limit cell proliferation, possibly by involving HO-1 signaling but not affecting 
endogenous ROS levels. 
The FA-tagged protein nanoemulsions loaded with CORM-2 led to considerable 
antitumor activity and the enhanced survival of mice bearing A20 lymphoma tumors. 
One possibility to explain this notable antitumor activity of FA-tagged nanoemulsions 
loaded with CORM-2 is the reported CO’s anti-cancer effect as a result of inducing anti-
Warburg effect.
14
 The Warburg effect provides substrates for cell growth and division 
and free energy (adenosine triphosphate, ATP) from enhanced glucose uptake and 
elevated glycolysis with a limited oxygen consumption rate.
14, 31
 Exposure to CO uses 
this effect compelling the cancer cell to consume more oxygen that in turn drives 
metabolic demand, leading to growth inhibition, cellular exhaustion and death.
14
 
In the present study we chose a syngeneic model of B-cell lymphoma in the 
BALB/c mouse, which mimics human disease in an immunocompetent host. The 
subcutaneous model presents advantages such as visual confirmation that mice used in 
an experiment have tumors prior to therapy; and assessment to tumor response or 
growth over time.
30
 Subcutaneous models may however be promiscuous of small 
particle penetration.
32
 Thus the effectiveness of targeting and effect over disease 
progression should be further supported, in future experiments in vivo, in an orthotopic 
fat-pad model or a disseminated lymphoma model to avoid this issue. 
Small size, high stability over time, specific targeting capacity and non-
immunogenicity supports their application as drug delivery systems. Therefore, these 
novel FA-functionalized PEGylated BSA nanoemulsions are promising nanocarriers for 
the selective delivery of drugs to a target cell population that express FR. In this way, 
these functionalized nanocarriers may ameliorate the side effects and low efficacy of 
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conventional cancer treatments. Furthermore, a number of new targeting ligands 
specific to B-cell lymphoma have been recently disclosed,
26
 constituting attractive 
targets for building functionalized protein nanoemulsions for cancer drug delivery with 
maximum specificity. 
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Figure legends 
Figure 1. Evaluation of FA-tagged protein nanoemulsions using FR positive cancer cell 
line.  
(A) β-actin and FR-alpha protein expression in KB, A20 and K562 cell lines analysed 
by Western blot. (B) 3D representations of images obtained by confocal microscopy of 
nanoemulsions internalization in A20 cell line, after 4 hours of incubation (scale bars = 
5 µm) (Blue = nuclear staining; Green = nanoemulsion particles; Red = phalloidin 
cytoskeleton staining).  
 
Figure 2.  In vitro therapeutic efficacy of CORM-2 and FA-tagged protein 
nanoemulsions loaded with CORM-2 in A20 cell line. 30% (v/v) of DMSO was 
nominated as death control. To correct for variation, raw data were converted in 
percentage of cell viability, relative to the “cell-only” control.  
(A) A20 cell line viability after 48 hours of contact with different concentrations of 
CORM-2. Values are the mean ± SEM of 2 independent experiments. (B) A20 cell line 
viability after 48 hours of contact with 300 µg/mL of BSA nanoemulsions, with and 
without 6 µM of CORM-2 and the free-drug. Values are the mean ± SEM of 2 
independent experiments. Different letters indicate significant differences among 
treatments (P<0.05, one-way ANOVA). 
 
Figure 3. In vivo therapeutic efficacy of FA-tagged protein nanoemulsions loaded with 
CORM-2.  
(A) Tumor growth curves of immunocompetent 10-week-old female BALB/c mice 
bearing subcutaneous A20 lymphoma tumors treated intravenously with FA-
functionalized nanoemulsions loaded CORM-2 (targeting FR), FA-functionalized 
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nanoemulsions (carrying no drug), CORM-2 (non-targeted delivery of drug), or saline. 
Treatment was performed daily for a period of 5 days (arrows). Data represent mean 
tumor volumes (±SE). Tumor growth curves were stopped when tumors reached a size 
of 1000 mm
3
. (B) Survival curves of mice treated with FA-functionalized 
nanoemulsions loaded CORM-2 and control groups. (C) Mice body weight variations 
during and after therapy. 
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Table 1. Conditions used for nanoemulsion preparation. 
BSA solution/vegetable oil ratio (v/v) 99,5% / 0,5% 
BSA-FITC/BSA ratio (m/m) 1/20 
BSA-FA conjugate/BSA ratio (m/m)  1/100 
BSA/FA (mol/mol) in BSA-FA conjugate 1/35 
 
 
Table 2. Characterization of nanoemulsions and FA-tagged nanoemulsions loaded with 
CORM-2. 
 
Z-average  
(d.nm) 
Polydispersity 
index (PDI) 
Zeta-potential 
(mV) 
FA 
concentration 
(µg/L) 
 
Nanoemulsions 93.7 (±8.2) 0.157 (±0.033) -1.82 (±0.15) - 
 
 
FA-Nanoemulsions 
+CORM-2 
90.9 (±5.1) 0.152 (±0.032) -2.28 (±0.25) 449.3 (±19.7) 
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Graphical Abstract 
 
A novel therapeutic approach using folic acid (FA)-tagged protein nanoemulsions, as 
targeting carrier, and Carbon-Monoxide Releasing Molecule 2 (CORM-2) was 
described and discussed. FA-tagged protein nanoemulsions loaded with CORM-2, a 
hydrophobic anti-proliferative drug, induce a strong antitumor effect and increased the 
survival of mice bearing subcutaneous A20 lymphoma tumors. 
 
 
